Cargando…
Immunoglobulin G4-related kidney diseases: An updated review
This review will encompass definition, pathogenesis, renal clinical manifestations and treatment of immunoglobulin G4-related diseases (IgG4-RDs). IgG4-RD is a recently recognized clinical entity that often involves multiple organs and is characterized by high levels of serum immunoglobulins G4, den...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760510/ https://www.ncbi.nlm.nih.gov/pubmed/29359118 http://dx.doi.org/10.5527/wjn.v7.i1.29 |
_version_ | 1783291369716973568 |
---|---|
author | Salvadori, Maurizio Tsalouchos, Aris |
author_facet | Salvadori, Maurizio Tsalouchos, Aris |
author_sort | Salvadori, Maurizio |
collection | PubMed |
description | This review will encompass definition, pathogenesis, renal clinical manifestations and treatment of immunoglobulin G4-related diseases (IgG4-RDs). IgG4-RD is a recently recognized clinical entity that often involves multiple organs and is characterized by high levels of serum immunoglobulins G4, dense infiltration of IgG4(+) cells and storiform fibrosis. Cellular immunity, particularly T-cell mediated immunity, has been implicated in the pathogenesis of IgG4-RDs. The most frequent renal manifestations of IgG4-RD are IgG4-related tubulointerstitial nephritis, membranous glomerulopathy and obstructive nephropathy secondary to urinary tract obstruction due to IgG4-related retroperitoneal fibrosis. IgG4-RD diagnosis should be based on specific histopathological findings, confirmed by tissue immunostaining, typical radiological findings and an appropriate clinical context. The first line treatment is the steroids with two warnings: Steroid resistance and relapse after discontinuation. In the case of steroid resistance, B cell depleting agents as rituximab represent the second-line treatment. In the case of relapse after discontinuation, steroid treatment may be associated with steroid sparing agents. Since the disease has been only recently identified, more prospective, long-term studies are needed to an improved understanding and a more correct and safe treatment. |
format | Online Article Text |
id | pubmed-5760510 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-57605102018-01-22 Immunoglobulin G4-related kidney diseases: An updated review Salvadori, Maurizio Tsalouchos, Aris World J Nephrol Review This review will encompass definition, pathogenesis, renal clinical manifestations and treatment of immunoglobulin G4-related diseases (IgG4-RDs). IgG4-RD is a recently recognized clinical entity that often involves multiple organs and is characterized by high levels of serum immunoglobulins G4, dense infiltration of IgG4(+) cells and storiform fibrosis. Cellular immunity, particularly T-cell mediated immunity, has been implicated in the pathogenesis of IgG4-RDs. The most frequent renal manifestations of IgG4-RD are IgG4-related tubulointerstitial nephritis, membranous glomerulopathy and obstructive nephropathy secondary to urinary tract obstruction due to IgG4-related retroperitoneal fibrosis. IgG4-RD diagnosis should be based on specific histopathological findings, confirmed by tissue immunostaining, typical radiological findings and an appropriate clinical context. The first line treatment is the steroids with two warnings: Steroid resistance and relapse after discontinuation. In the case of steroid resistance, B cell depleting agents as rituximab represent the second-line treatment. In the case of relapse after discontinuation, steroid treatment may be associated with steroid sparing agents. Since the disease has been only recently identified, more prospective, long-term studies are needed to an improved understanding and a more correct and safe treatment. Baishideng Publishing Group Inc 2018-01-06 2018-01-06 /pmc/articles/PMC5760510/ /pubmed/29359118 http://dx.doi.org/10.5527/wjn.v7.i1.29 Text en ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Salvadori, Maurizio Tsalouchos, Aris Immunoglobulin G4-related kidney diseases: An updated review |
title | Immunoglobulin G4-related kidney diseases: An updated review |
title_full | Immunoglobulin G4-related kidney diseases: An updated review |
title_fullStr | Immunoglobulin G4-related kidney diseases: An updated review |
title_full_unstemmed | Immunoglobulin G4-related kidney diseases: An updated review |
title_short | Immunoglobulin G4-related kidney diseases: An updated review |
title_sort | immunoglobulin g4-related kidney diseases: an updated review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760510/ https://www.ncbi.nlm.nih.gov/pubmed/29359118 http://dx.doi.org/10.5527/wjn.v7.i1.29 |
work_keys_str_mv | AT salvadorimaurizio immunoglobuling4relatedkidneydiseasesanupdatedreview AT tsalouchosaris immunoglobuling4relatedkidneydiseasesanupdatedreview |